{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Baquedano L"],"pubmed_abstract":["<h4>Objective</h4>To study what women think about menopause treatments and assess their knowledge about them. To analyze adherence to treatment during COVID-19 confinement as a secondary objective.<h4>Methods</h4>A multi-center cross-sectional observational study was conducted using a survey of 2500 women between January and June 2019. This was administered following a non-probability sampling procedure including women between 35 and 75 years. An extension study was conducted during the coronavirus pandemic, between March and June 2020.<h4>Results</h4>The responses of 2355 surveyed women were analyzed. Of this sample, 42% knew about menopause hormone therapy (MHT). The most frequently identified indication was the treatment of hot flashes (65.6%). The MHT risks most frequently perceived we"],"journal":["BMC women's health"],"pagination":["277"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7768270"],"repository":["biostudies-literature"],"pubmed_title":["Beliefs, knowledge and the impact of COVID19 on menopause therapies in Spanish women: COMEM-treatment study."],"pmcid":["PMC7768270"],"pubmed_authors":["Baquedano L","Gabasa L","Choliz M","Presa J","Mendoza N","Borque A","Roy V","Yague H","Coronado PJ","Llaneza P","Fasero M","COMEM Study Spanish investigators","Rubio P","Palacios S","Negredo I","Sanchez-Borrego R","Ruiz L","Villalobos F","Colmenarejo F","Lamarca M","Del Tiempo P","Gutierrez L","Hernnandez M","Dieste P","Ramirez I","Jose Y","Espiau A","Cotaina L","Ortega S","Puente MJ","Aznar T","Tajada PD","Jurado AR"],"additional_accession":[]},"is_claimable":false,"name":"Beliefs, knowledge and the impact of COVID19 on menopause therapies in Spanish women: COMEM-treatment study.","description":"<h4>Objective</h4>To study what women think about menopause treatments and assess their knowledge about them. To analyze adherence to treatment during COVID-19 confinement as a secondary objective.<h4>Methods</h4>A multi-center cross-sectional observational study was conducted using a survey of 2500 women between January and June 2019. This was administered following a non-probability sampling procedure including women between 35 and 75 years. An extension study was conducted during the coronavirus pandemic, between March and June 2020.<h4>Results</h4>The responses of 2355 surveyed women were analyzed. Of this sample, 42% knew about menopause hormone therapy (MHT). The most frequently identified indication was the treatment of hot flashes (65.6%). The MHT risks most frequently perceived we","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-04-19T08:16:28.353Z","creation":"2021-02-20T17:15:05Z"},"accession":"S-EPMC7768270","cross_references":{"pubmed":["33371883"],"doi":["10.1186/s12905-020-01151-x"]}}